In IMU's defense, CG Oncology's market cap is over $2 billion...

In IMU's defense, CG Oncology's market cap is over $2 billion USD. So, focusing on market research for oncology viruses, where only one has been FDA approved, doesn't fully consider potential future approvals. As for the time range of 2021-2024, it does seem broad. Typically, using data more than 10 years old might not capture recent developments accurately.But comparing IMU's phase 1 data with CG0070 is quite depressing. For the sake of shareholders, let's hope that pseudoprogression proves to be significant and patients have a more favourable outcome, or the expansion cohort is a massive success. Otherwise IMU is going to have to try and acquire another drug and rinse and repeat. lol